ESC 365 - Effectiveness, adherence and safety of evolocumab in a Swiss multicenter prospective observational study

ESC Premium Access

Effectiveness, adherence and safety of evolocumab in a Swiss multicenter prospective observational study

Session: Risk Factors and Prevention ePosters

Topic: Drug therapy

Speaker: Doctor D. Nanchen (Lausanne, CH)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor David Nanchen

University of Lausanne, Lausanne (Switzerland)

0 follower

224 more presentations in this session

High risk characteristics in patients with hypertrophic cardiomiyopathy for predicting cardiovascular events

Speaker: Doctor B. Keskin (Istanbul, TR)

Cardiac biomarkers as prognosticators among SARS-CoV-19 patients in a tertiary hospital in Philippines

Speaker: Doctor R. Ong (Makati, PH)

Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndromes; final data of the nationwide cross-sectional CardioRisk project

Speaker: Doctor A. Bendary (Benha, EG)

SF-12 Physical and Mental Health Scales predict cardiovascular events after hospitalization

Speaker: Mr R. Gascuena (Leganes, ES)

Comparison of traditional versus artificial intelligence based coronary artery disease risk prediction scores in young patients with acute coronary syndrome

Speaker: Doctor S. Vohra (Lucknow, IN)

Access the full session

Risk Factors and Prevention ePosters

Speakers: Doctor D. Nanchen, Doctor B. Keskin, Doctor R. Ong, Doctor A. Bendary, Mr R. Gascuena...

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Comparing Rivaroxaban and Apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria

27 August 2021

ESC Premium Access

Potential cardiovascular risk reduction with evolocumab in the real world: a simulation in patients with a history of myocardial infarction from the HEYMANS register

27 August 2021

ESC Premium Access

Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials

27 August 2021

ESC 365 is supported by